Steven M. Kawut, M.D., M.S.

Associate Professor of Medicine and Epidemiology
Director, Pulmonary Vascular Disease Program
Penn Cardiovascular Institute
Center for Clinical Epidemiology and Biostatistics

University of Pennsylvania Medical Center
Pulmonary, Allergy & Critical Care Division
711 Blockley Hall
423 Guardian Dr.
Philadelphia, PA 19104
tel.: (215) 573-0258
email: kawut@mail.med..upenn.edu

Education:

MD: Yale School of Medicine

MS University of Pennsylvania School of Medicine

Fellowship: Hospital of the University of Pennsylvania

Residency: Hospital of the University of Pennsylvania

Dr. Kawut completed his medical degree at Yale School of Medicine before completing his residency in internal medicine, fellowship in pulmonary and critical care medicine, and Master of Science degree at Penn. He recently returned to Penn after being the Herbert Irving Assistant Professor of Clinical Medicine and Epidemiology at Columbia University College of Physicians and Surgeons.

He is boarded in Internal Medicine and Pulmonary and Critical Care Medicine and provides clinical care in pulmonary vascular disease and lung transplantation. In addition to continuing his clinical activities, he has also pursued an active clinical research career.

Dr. Kawut is an Associate Professor of Medicine and Epidemiology in the Center for Clinical Epidemiology and Department of Medicine, Director of the research program in pulmonary vascular disease in the Penn Cardiovascular Institute , and Director of the Pulmonary Vascular Disease Program at the University of Pennsylvania School of Medicine. His clinical interests are primarily in pulmonary hypertension and lung transplantation and his research interests are focused on the epidemiology and treatment of pulmonary vascular disease, right ventricular dysfunction, and lung transplant candidates.

Dr. Kawut holds grants from the National Institutes of Health. He has served on grant review committees of the National Institutes of Health, the American Lung Association, and other sponsors. He has published over 60 peer-reviewed papers, along with numerous review articles and book chapters. He has spoken at and chaired numerous national and international meetings. He is an associate editor of the European Respiratory Journal, and regularly reviews manuscripts for many scientific journals.

Research Program I
Epidemiology and Treatment of Pulmonary Vascular Disease
The risk factors and outcomes of pulmonary arterial hypertension and other forms of pulmonary vascular disease are a major focus of research. Our group also investigates new therapies for pulmonary vascular disease.

Research Program II
Determinants of Right Ventricular Function in Health and Disease

Research Program III
Predictors of Outcomes in Lung Transplantation
Our group has published several studies of the complications of lung transplantation.

Representative Publications:

Research Program I
Roberts KE, Fallon MB, Krowka MJ, Benza RL, Knowles JA, Badesch DB, Brown RS, Taichman DB, Trotter J, Zacks S, Horn EM, Kawut SM. Serotonin transporter polymorphisms in patients with portopulmonary hypertension. Chest 2009;135:1470-5.

Roberts KE, Fallon MB, Krowka MJ, Benza RL, Knowles JA, Badesch DB, Brown RS, Taichman DB, Trotter J, Zacks S, Horn EM, Kawut SM. Serotonin transporter polymorphisms in patients with portopulmonary hypertension. Chest 2009;135:1470-5.

Roberts KE, Fallon MB, Krowka MJ, Brown RS, Trotter JF, Peter I, Tighiouart H, Knowles JA, Rabinowitz D, Benza RL, Badesch DB, Taichman DB, Horn EM, Zacks S, Kaplowitz N, Kawut SM for the PVCLD Study Group. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Resp Crit Care Med 2009;179:835-842.

Lederer DJ, Horn EM, Rosenzweig EB, Karmally W, Jahnes, M, Barst RJ, Kawut SM. Plasma serotonin levels are normal in pulmonary arterial hypertension. Pulm Pharmacol Ther 2008;21:112-4.

Kawut SM, Horn EM, Berekashvili KK, Lederer DJ, Widlitz AC, Berman-Rosenzweig ES, Barst RJ. Selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension. Pulm Pharm Ther 2006;19:370-374

Robbins IM*, Kawut SM*, Yung D, Reilly M, Lloyd W, Cunningham G, Loscalzo J, Kimmel SE, Christman B, Barst RJ.  A study of aspirin and clopidogrel in pulmonary arterial hypertension. ERJ 2006;27:578-584. *Equal contribution.

Kawut SM, Horn EM, Berekashvili KK, Widlitz AC, Rosenzweig EB, Barst RJ. Von Willebrand factor independently predicts long-term survival in patients with pulmonary arterial hypertension. Chest 2005;128:2355-2362.

Kawut SM, Taichman DB, Ahya VN, Kaplan S, Archer-Chicko CL, Kimmel SE, Palevsky HI. Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transplantation 2005;11:1107-1111.

Research Program II
Kawut SM, Al-Naamani N, Agerstrand C, Berman-Rosenzweig ES, Rowan C, Barst RJ, Bergmann S, Horn EM. Determinants of right ventricular ejection fraction in pulmonary arterial hypertension. Chest 2009;135:752-759.

Research Program III
Kawut SM, Okun J, Shimbo D, Lederer DJ, DeAndrade J, Lama V, Milstone A, Ware LB, Weinacker A, Demissie E, Christie JD. Soluble P-selectin and the risk of primary graft dysfunction after lung transplantation. Chest (In Press).

Kawut SM, Lederer DJ, Keshavjee S, Wilt JS, D’Ovidio F, Sonett JR, Arcasoy SM, Barr M. Outcomes after lung retransplantation in the modern era. Am J Resp Crit Care Med 2008;177:114-120.

Al-Naamani N, Maarouf OH, Wilt JS, Bacchetta M, D'Ovidio F, Sonett, JR, Arcasoy SM, Lederer DJ, Nickolas TL, Kawut SM. The Modification of Diet in Renal Disease (MDRD) and the prediction of kidney outcomes after lung transplantation. J Heart Lung Transplant 2008;27:1191-1197.

revised 7/09